



PHARMA EQUITY GROUP

28. February 2025

News Release:

The board has decided that Pharma Equity Group A/S will in future only submit half-yearly financial reports.

This means changes to the previously announced financial calendar for 2025. The current financial calendar for 2025 will look like this:

Pharma Equity Group 2025 Financial Calendar	
March 4	Deadline for shareholder proposals - Annual General meeting
March 20	Annual Report 2024
April 16	Annual General Meeting
August 14	Interim Report – for the six-month period ended June 30, 2025

Contact person – Investor Relations

On the Company's website www.pharmaequitygroup.com further information and all published announcements can be found.

Inquiries regarding relations with investors and the stock market can be directed to: Thomas Kaas Selsø, CEO, Phone: +45 4022 2114 E-mail: investor@pharmaequitygroup.com.

About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.



PHARMA EQUITY GROUP

28. februar 2025

Pressemeddelelse:

Bestyrelsen har d.d. besluttet, at Pharma Equity Group A/S fremover kun aflægger finansielle halvårsrapporter.

Dette betyder ændringer til den tidligere udmeldte finanskalender for 2025. Den gældende finanskalender for 2025 kommer til at se således ud:

Pharma Equity Group Finanskalender for 2025	
4. marts	Frist for aktionærforslag - Ordinær generalforsamling
20. marts	Årsrapport 2024
16. april	Ordinær generalforsamling
14. august	Delårsrapport – for halvåret, der sluttede 30. juni 2025

Kontaktperson – Investor Relations

På selskabets hjemmeside www.pharmaequitygroup.com kan yderligere information og alle offentliggjorte meddelelser findes.

Henvendelser vedrørende Investor Relations og aktiemarkedet kan rettes til: Thomas Kaas Selsø, CEO, Telefon: +45 4022 2114 E-mail: investor@pharmaequitygroup.com.

Om Pharma Equity Group A/S

Pharma Equity Group er et børsnoteret selskab på Nasdaq Copenhagens hovedliste. Selskabets hovedfokus er på at fremme de forskellige lægemiddelkandidater i sit datterselskab, Reponex Pharmaceuticals A/S. Med et urokkeligt fokus på Health Care er Pharma Equity Groups primære mål at tilføre betydelig værdi til Reponex Pharmaceuticals' forskellige lægemiddelkandidater.

Selskabet er forpligtet til at yde omfattende support, ressourcer og ekspertise til at drive udviklingen og succesen af disse lægemiddelkandidater. Som strategisk partner arbejder Pharma Equity Group tæt sammen med Reponex Pharmaceuticals og prioriterer fremme af innovative medicinske løsninger og banebrydende behandlinger. Denne tilgang sikrer et stærkt engagement i de aktuelle medicinske projekter og deres udvikling, samtidig med at den – på længere sigt – forbliver åben for nye strategiske investeringer med henblik på fortsat vækst.